The Myriad Case: So many issues, so little time!

International Society for Philosophy, History and Social Sciences of Biology

11 July 2013

Robert Cook-Deegan, MD
Institute for Genome Sciences & Policy
Sanford School of Public Policy
Duke University
Disclosure

• I remain on the Jeanne Lenzer/Shannon Brownlee list of health professionals who do not consult or accept funding from pharma/biotech/device companies:
  
  Naming names: is there an (unbiased) doctor in the house?  
  BMJ 2008; 337 doi: 10.1136/bmj.a930 (Published 23 July 2008)
  List maintained by HealthNewsReview.org

• The funding sources for our research are the National Institutes of Health (P50 HG003391), The Duke Endowment, and the Ewing Marion Kauffman Foundation, with occasional contracts or specific projects for the World Health Organization, Food and Agriculture Organization, World Intellectual Property Organization, GAVI, Josiah Trent Foundation, and Fondation Brocher
The Myriad Case: Great Case, wrong lessons

- Suit happened not because advocates worry about monopoly, but because they were concerned about who makes medical decisions
  - Price an issue, but not the main issue
  - Dislike of business practices, not of patents *per se*
  - Line of attack = patents
The Myriad Cases: The Neverending story

- Supreme Court decision that cDNA is patentable and gDNA is not
- Myriad sues Ambry and Gene to Gene
- If I discover mutations in a gene associated with inherited cancer risk, can I block competitors from doing PCR on the mutated gene (even if BRCA1/2 are just two among many genes being assessed)?
- Myriad has pledged not to sue for academic nonprofit research use or verification testing
The other issue: trade secrets

- Myriad’s proprietary database drawing on ~1 million tests
- Leveraged on sole-provider status in US
- Does not expire with patents
- Myriad claiming 2% variants of unknown significance (VUS) compared to 30% for Euro competitors
The long tail of mutation

• Most common mutations are usually discovered first

• Patents and IP established on first discovery

• Two decades and >1 million tests later, we are still finding mutations in *BRCA* genes

• *BRCA1/2* have been joined by ~20 other genes in conferring risk for breast/ovarian cancer
Different cases

- AMP v Myriad was public interest case
- Current cases are more conventional conflicts among competitors
Merton’s CUDOS

- Communal (shared)
- Universal
- Disinterested
- Original
- Skeptical
Restatements of independent verification in genomics

- **Cech report** *(Sharing Publication-Related Data and Materials)* 2002, National Research Council
- **Omics report** *(Evolution of Translational Omics)* 2012, Institute of Medicine
- **Precision Medicine report** *(Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease)* 2012, Institute of Medicine